Working… Menu
Trial record 47 of 213 for:    "Hypogonadism" | "Androgens"

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01270841
Recruitment Status : Completed
First Posted : January 5, 2011
Results First Posted : July 28, 2014
Last Update Posted : July 28, 2014
Information provided by (Responsible Party):
Repros Therapeutics Inc.

Brief Summary:
The Purpose of the study is to determine the effects of Androxal on morning testosterone and reproductive status in men with secondary hypogonadism(confirmed morning Testosterone less than 250 ng/dL), compared to changes with placebo, or Testim (topical testosterone). The effects of Testim versus placebo on reproductive status will also be examined. Study subjects must not be currently using a topical testosterone.

Condition or disease Intervention/treatment Phase
Secondary Hypogonadism Drug: Placebo Drug: topical testosterone Drug: Androxal Phase 2

Detailed Description:
This study is a phase IIb, 4 arm study with three month active dosing period. Three of the four treatment groups will be randomized to either Androxal or placebo in a double-blind fashion, and the fourth treatment group will receive open-label Testim. The doses of Androxal in the blinded portion of the study will be 12.5 mg and 25 mg, in capsule form.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 83 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism
Study Start Date : January 2011
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
Drug: Placebo
Placebo capsule 1x daily for 3 months

Active Comparator: Testim (topical testosterone)
Testim (topical testosterone)
Drug: topical testosterone
testosterone gel applied 1x daily for 3 months
Other Names:
  • Testim
  • AndroGel

Experimental: Androxal 12.5 mg
Androxal 12.5 mg/day
Drug: Androxal
Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
Other Name: Enclomiphene citrate

Experimental: Androxal 25 mg
Androxal 25 mg/day
Drug: Androxal
Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
Other Name: Enclomiphene citrate

Primary Outcome Measures :
  1. Change in Total Morning Testosterone [ Time Frame: 3 months ]
    Changes in values from baseline in total morning testosterone levels at month 3 comparing Androxal 12.5 and 25 mg to placebo and Testim

Secondary Outcome Measures :
  1. Change in Luteinizing Hormone Levels [ Time Frame: 3 months ]
    Changes in values from baseline in LH at month 3

  2. Change in FSH After 3 Months of Treatment [ Time Frame: 3 months ]
  3. Reproductive Safety [ Time Frame: 3 months ]
    Change from baseline in sperm concentration

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy males between the ages of 21 and 65 years of age
  • All clinical laboratory tests within normal ranges (any clinically significant deviation of laboratory results will require approval of sponsor)
  • Previously or concurrently diagnosed as having secondary hypogonadism and confirmed morning testosterone <250ng/dL (two assessments at least 10 days apart)
  • Ability to complete the study in compliance with the protocol
  • Ability to understand and provide written informed consent
  • Agreement to use double barrier contraception if with a fertile female partner
  • Agreement to provide a semen sample in the clinic

Exclusion Criteria:

  • Use of an injectable, oral, topical, or subcutaneous pelleted testosterone within 6 months prior to study
  • Use of spironolactone, cimetidine, Clomid, 5α-reductase inhibitors, hCG, androgen, estrogen, anabolic steroid, DHEA, or herbal hormone products during the study
  • Use of Clomid in the past year
  • Uncontrolled hypertension or diabetes mellitus based on the Investigator's assessment at baseline. Subjects treated for Type II diabetes but exhibiting glycemic control will be allowed into the study
  • A hematocrit >50% or a hemoglobin >17 g/dL
  • Clinically significant abnormal findings on screening examination
  • Use of an investigational drug or product, or participation in a drug or medical device research study within 30 days prior to receiving study medication
  • Known hypersensitivity to Clomid
  • Symptomatic cataracts (nuclear sclerosis cataract or cortical cataract grade > 2 based on 0-4 scale or any trace of posterior subcapsular cataract)
  • Any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the study
  • Irreversibly infertile or compromised fertility (cryptorchism, Kallman Syndrome, primary hypogonadism, vasectomy, or tumors of the pituitary)
  • Current or history of breast cancer
  • Current or history of prostate cancer or a suspicion of prostate disease unless ruled out by prostate biopsy, or a PSA>3.6
  • Presence or history of hyperprolactinemia with or without a tumor
  • Chronic use of medications use such as glucocorticoids
  • Subjects with cystic fibrosis (mutation of the CFTR gene)
  • Subjects unable to provide a semen sample in the clinic
  • Subject has a BMI >36 kg/m2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01270841

Layout table for location information
United States, California
Paradigm Clinical Inc.
Garden Grove, California, United States, 92844
Northern California Research Corp
Sacramento, California, United States, 95831
Medical Center for Clinical Research
San Diego, California, United States, 92108
Los Angeles Biomedical Research Institute
Torrance, California, United States, 90502
United States, Nevada
Affiliated Clinical Research
Las Vegas, Nevada, United States, 89109
Affiliated Clinical Research Inc.
Las Vegas, Nevada, United States, 89144
United States, New York
Weill Cornell Medical College and Smith Institute
Great Neck, New York, United States, 11021
Jed Kaminetsky
New york, New York, United States, 10016
Natan Bar-Chama
New York, New York, United States, 10022
Michael A Werner
Purchase, New York, United States, 10577
United States, Texas
Discovery Clinical Trials
Austin, Texas, United States, 78758
Research Across America
Carrollton, Texas, United States, 75010
Texas Urology Specialist
Houston, Texas, United States, 77024
Centex Research
Houston, Texas, United States, 77062
Endocrine and Psychiatry Center
Houston, Texas, United States, 77095
Protenium Clinical Research
Hurst, Texas, United States, 76054
R/D Clinical Research
Lake Jackson, Texas, United States, 77566
Cetero Research
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Repros Therapeutics Inc.
Layout table for investigator information
Principal Investigator: Larry Lipshultz, MD Baylor College of Medicine

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Repros Therapeutics Inc. Identifier: NCT01270841     History of Changes
Other Study ID Numbers: ZA-203
First Posted: January 5, 2011    Key Record Dates
Results First Posted: July 28, 2014
Last Update Posted: July 28, 2014
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Gonadal Disorders
Endocrine System Diseases
Testosterone undecanoate
Testosterone enanthate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents
Estrogen Antagonists
Hormone Antagonists
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators